Literature DB >> 12649336

Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjögren's syndrome.

Peter Szodoray1, Stig Jellestad, Maria Ohlsson Teague, Roland Jonsson.   

Abstract

B cell activating factor (BAFF) is known to be a powerful regulator of B-cell differentiation and proliferation. The aim of this study was to assess the incidence of apoptosis among BAFF-expressing cells in Sjögren's syndrome (SS) salivary gland tissue. We performed double stainings of BAFF together with one of the markers, CD21, CD68, CD40, Fas, Bcl-2 or Bax, and monitored apoptosis among BAFF expressing cells by using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-digoxigenin nick-end labeling method. A significantly lower level of apoptosis among the BAFF-expressing cells was detected in salivary glands from patients with SS compared with controls (p = 0.03). Furthermore, no difference in the coexpression of Fas or CD40 together with BAFF was detected between patients and controls. Coexpression of the pro apoptotic molecule Bax together with BAFF was nonsignificantly decreased in patients with SS compared with controls. Our results suggest that a reduced level of apoptosis among BAFF-expressing cells might lead to longer-existing BAFF expression within these cells and thereby maintain signaling for tissue-infiltrating B cells to proliferate and mature.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649336

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  20 in total

Review 1.  Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjögren's syndrome.

Authors:  Roland Jonsson; Tom P Gordon; Yrjö T Konttinen
Journal:  Curr Rheumatol Rep       Date:  2003-08       Impact factor: 4.592

2.  Lymphoma and other malignancies in primary Sjögren's syndrome.

Authors:  S R Pillemer
Journal:  Ann Rheum Dis       Date:  2006-06       Impact factor: 19.103

3.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.

Authors:  Clio P Mavragani; Timothy B Niewold; Niki M Moutsopoulos; Stanley R Pillemer; Sharon M Wahl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2007-12

Review 4.  T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology.

Authors:  Gikas E Katsifis; Niki M Moutsopoulos; Sharon M Wahl
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 5.  Unraveling the pathophysiology of Sjogren syndrome-associated dry eye disease.

Authors:  Cuong Q Nguyen; Ammon B Peck
Journal:  Ocul Surf       Date:  2009-01       Impact factor: 5.033

6.  Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation.

Authors:  Luca Quartuccio; Martina Fabris; Sara Salvin; Marta Maset; Ginevra De Marchi; Salvatore De Vita
Journal:  Int J Rheumatol       Date:  2010-01-28

Review 7.  Stromal cell regulation of homeostatic and inflammatory lymphoid organogenesis.

Authors:  Matthew J W Kain; Benjamin M J Owens
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

Review 8.  Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.

Authors:  Michael Voulgarelis; Fotini N Skopouli
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 9.  The importance of non-HLA antibodies in transplantation.

Authors:  Qiuheng Zhang; Elaine F Reed
Journal:  Nat Rev Nephrol       Date:  2016-06-27       Impact factor: 28.314

10.  Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma.

Authors:  Zhaoyang Li; Hongsheng Wang; Liquan Xue; Dong-Mi Shin; Derry Roopenian; Wu Xu; Chen-Feng Qi; Mark Y Sangster; Carlos J Orihuela; Elaine Tuomanen; Jerold E Rehg; Xiaoli Cui; Quangeng Zhang; Herbert C Morse; Stephan W Morris
Journal:  Blood       Date:  2009-08-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.